Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer

Onkologie

Volumn 30, Issue 8-9, 2007, Pages 421-426

  Szöke, Dominika ^a   Györffy, András ^a   Surowiak, Paweł ^b   Tulassay, Zsolt ^a   Dietel, Manfred ^b   Györffy, Balázs ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

5 Fluorouracil; Gastric and colon cancer; Gene expression signature; Promoter; Transcription factor

Indexed keywords

FLUOROURACIL; TRANSCRIPTION FACTOR; ANTINEOPLASTIC AGENT; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BINDING SITE; COLON CANCER; COMPUTER PROGRAM; CONSENSUS; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENETIC RESISTANCE; PROMOTER REGION; REGULATORY SEQUENCE; STOMACH CANCER; TUMOR CELL; WEB BROWSER; COLON TUMOR; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; RETROSPECTIVE STUDY; STOMACH TUMOR;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 35348822435     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104490     Document Type: Article

References (40)

1. Bokemeyer C, Honecker F: Chemotherapy of advanced colorectal carcinoma: treatment options for elderly patients. Onkologie 2003;26(suppl 7):48-53.
2. Kohne CH: Palliative therapy of colorectal cancer. Onkologie 2003;26(suppl 7):41-47.
3. Al-Batran SE, Kerber A, Atmaca A, Dechow C, Reitsamer E, Schmidt S, Kolassa Y, Neumann A, Weidmann E, Hartmann JT, Jager E: Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Onkologie 2007;30:29-34.
4. Hofheinz RD, Kubicka S, Wollert J, Arnold D, Hochhaus A: Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin-refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft fur Internistische Onkologie (AIO). Onkologie 2006;29:563-567.
5. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG: Genetic factors influencing pyrimidineantagonist chemotherapy. Pharmacogenomics J 2005;5:226-243.
6. Peters GJ, Backus HHJ, Freemantle S, Triest B, Codacci-Pisanelli G, Wilt CL, Smid K, Lunec L, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, Groeningen CJ, Pinedo HM: Induction of thymidylate synthase as a 5-FU resistance mechanism. Biochim Biophys Acta 2002;1587:194-205.
7. Lenz HJ: Molecular markers in gastrointestinal cancer: targeted therapy and tailored chemotherapy. Onkologie 2004;27:12-14.
8. De Angelis PM, Svendsrud DH, Kravik KL, Stokke T: Cellular response to 5-fluorouracil (5-FU) in 5-FU resistant colon cancer cell lines during treatment and recovery. Mol Cancer 2006;5:20.
9. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E: Mechanistic and predictive profiling of 5-FU resistance in human cancer cells. Cancer Res 2004;64:8167-8176.
10. Schmidt WM, Kalipciyan M, Dornstauder E, Rizovski B, Steger GG, Sedivy R, Mueller MW, Mader RM: Dissecting progressive stages of 5-FU resistance in vitro using RNA expression profiling. Int J Cancer 2004;112:200-212.
11. Kim HK, Choi IJ, Kim HS, Kim JH, Kim E, Park IS, Chun JH, Kim IH, Kim IJ, Kang HC, Park JH, Bae JM, Lee JS, Park JG: DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Comm 2004;316:781-789.
12. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004;10:272-284.
13. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M, Lage H: Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006;118:1699-1712.
14. Zhang H, Ramanathanm Y, Soteropoulos P, Recce M, Tolias PP: EZ-Retrieve: a web-server for batch retrieval of coordinate-specified human DNA sequences and underscoring putative transcription factor-binding sites. Nucl Acids Res 2002;30:e121.
15. Matys V, Fricke E, Geffers R, Gößling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, Kloos DU, Land S, Lewicki-Potapov B, Michael H, Münch R, Reuter I, Rotert S, Saxel H, Scheer M, Thiele S, Wingender E: TRANSFAC: transcriptional regulation, from patterns to profiles. Nucl Acids Res 2003;31:374-378.
16. Aerts S, Thijs G, Coessens B, Staes M, Moreau Y, De Moor B: TOUCAN: deciphering the Cis-regulatory logic of coregulated genes. Nucl Acids Res 2003;31:1753-1764.
17. Mader RM, Muller M, Steger GG: Resistance to 5-FU. Gen Pharmacol 1998;31:661-666.
18. Baldwin AS Jr: The NF-kappa-B and I-kappa-B proteins: new discoveries and insights. Ann Rev Immunol 1996;14:649-683.
19. Chen F, Castranova V, Shi X, Demers LM: New insights into the role of nuclear factor-kappa-B, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17.
20. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-16647.
21. Yamamoto Y, Gaynor RB: Therapeutic potential of inhibition of the NF-kappa-B pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-142.
22. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappa-B functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466.
23. Garcia MG, Alaniz L, Lopes EC, Blanco G, Hajos SE, Alvarez E: Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005;29:1425-1434.
24. Azuma M, Yamashita T, Aota K, Tamatani T, Sato M: 5-FU suppression of NF-KappaB is mediated by the inhibition of IKappab kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 2001;282:292-296.
25. Butler MP, Hanly JA, Moynagh PN: Pellino3 is a novel upstream regulator of p38 MAPK and activates CREB in a p38-dependent manner. J Biol Chem 2005;280:27759-27768.
26. Peták I, Houghton JA: Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Path Oncol Res 2001;7:95-106.
27. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998;1;543-551.
28. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033-2045.
29. Hernandez-Vargas H, Rodriguez-Pinilla SM, Julian-Tendero M, Sanchez-Rovira P, Cuevas C, Anton A, Rios MJ, Palacios J, Moreno-Bueno G: Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007;102:157-172.
30. Baldwin AS Jr: Series introduction: the transcription factor NF-kappaB and human disease. J Clin Investig 2001;107:3-6.
31. Ehlert JE, Kubbutat MH: Apoptosis and its relevance in cancer therapy. Onkologie 2001;24:433-440.
32. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-417.
33. Cusack JC Jr, Liu R, Houston M, et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535-3540.
34. Singh NP, Nagarkatti M, Nagarkatti PS: Role of dioxin response element and nuclear factor-kappaB motifs in 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated regulation of Fas and Fas ligand expression. Mol Pharmacol 2007;71:145-157.
35. Grimm T, Schneider S, Naschberger E, Huber J, Guenzi E, Kieser A, Reitmeir P, Schulz TF, Morris CA, Sturzl M: EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 2005;105:3263-3269.
36. Schauvliege R, Vanrobaeys J, Schotte P, Beyaert R: Caspase-11 gene expression in response to lipopolysaccharide and interferon-gamma requires nuclear factor-kappa B and signal transducer and activator of transcription (STAT) 1. J Biol Chem 2002;277:41624-41630.
37. Catz SD, Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001;20:7342-7351.
38. Tourtellotte WG, Nagarajan R, Bartke A, Milbrand J: Functional compensation by Egr4 in Egr1-dependent luteinizing hormone regulation and Leydig cell steroidogenesis. Mol Cell Biol 2000;20:5261-5268.
39. Unoki M, Nakamura Y: EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene 2003;22:2172-2185.
40. Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, Mitsuya H, Matsuoka M: Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004;64:6002-6009.